Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma, T-Cell 2 Uveal Melanoma 1 Neuroendocrine Tumors 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Immunoblastic Lymphadenopathy 1 Eye Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 22 Nivolumab 14 enfortumab vedotin 13 Gemcitabine 11 Specimen Handling 9 Magnetic Resonance Spectroscopy 9 Cisplatin 8 Carboplatin 8 sacituzumab govitecan 6 Docetaxel 6 avelumab 5 atezolizumab 5 Ipilimumab 5 durvalumab 4 Paclitaxel 4 cabozantinib 3 Taxes 3 Mitomycin 3 CTLA-4 Antigen 3 tislelizumab 2 relatlimab 2 erdafitinib 2 disitamab vedotin 2 Radiosurgery 2 Platinum 2 Oxaliplatin 2 Immunoglobulin G 2 Fluorouracil 2 Disulfides 2 ALT-803 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × belinostat × 90 days × Clear all

NCT05154994 2026-05-07

RESOLVE

University of Utah

Phase 1 Active not recruiting

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡